-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Neutral on Outlook Therapeutics, Maintains $1 Price Target

Benzinga·09/30/2025 11:41:03
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $1 price target.